accretion/dilution analysis

What is the point of carrying out an accretion/dilution analysis?

I'm reading everywhere that the P/E gives no indication of the value creation of a deal. 

So I am wondering, what is it really for? Why should I, as a banker, be interested in calculating it (other than knowing that my P/E is going to fall for my shareholders, etc.)? 

Thanks

3 Comments
 
Most Helpful

You kinda answered it, and it's because public market perception is everything.

Public markets are "dumb" and care about EPS. If I'm a shareholder of your company and my Earnings Per Share goes down after you do this transaction, I'll perceive that as a bad deal for me and invest in a better stock. That means your stock price will go down, and you won't be able to raise as much capital in the future from selling shares. Which isn't ideal.

Of course, this is super simplified and it doesn't always pan out this way...but it's the basic rationale for why accretion dilution is always included. It's also not a dealbreaker for many reasons including the ones you mentioned. EPS isn't the end-all be-all. If it's accretive, that's great. If not, then the buyer (with the help of their trusty bankers!) needs to come up with clear, solid rationale for why the transaction creates value long-term in a way that their investors will respond positively to.

 

Take it back to basics. Pretend, for simplicity, that earnings really represents cash earnings, and that a company pays out every dollar of earnings as a dividend. If I own a share in a company that pays me a $5 dividend off of $5 EPS, and then the company does a deal that is dilutive, so now each share only has access to EPS of $4, which means a $4 dividend, then my share just lost 20% of its value. Unless, for some reason, that $4 became less risky now, the deal is near-term dilutive but long-term accretive, etc... But ultimately, any capital allocation decision should come down to whether it creates additional value for shareholders on a per share basis.

 

Molestiae dolores sed ea. Unde aliquam unde necessitatibus odit natus. Voluptatem et temporibus atque voluptate.

I'm an AI bot trained on the most helpful WSO content across 17+ years.

Career Advancement Opportunities

July 2026 Investment Banking

  • Evercore 01 99.4%
  • Moelis & Company 01 98.9%
  • JPMorgan 01 98.3%
  • Guggenheim Partners 01 97.7%
  • Morgan Stanley 07 97.1%

Overall Employee Satisfaction

July 2026 Investment Banking

  • Moelis & Company No 99.4%
  • Evercore No 98.9%
  • Morgan Stanley 01 98.3%
  • BMO Capital Markets 12 97.7%
  • Banco Santander 01 97.1%

Professional Growth Opportunities

July 2026 Investment Banking

  • Evercore 01 99.4%
  • Moelis & Company 01 98.9%
  • Morgan Stanley 06 98.3%
  • Goldman Sachs 01 97.7%
  • JPMorgan 01 97.1%

Total Avg Compensation

July 2026 Investment Banking

  • Vice President (15) $434
  • Associates (46) $258
  • 3rd+ Year Analyst (8) $210
  • 2nd Year Analyst (22) $179
  • Intern/Summer Associate (13) $156
  • 1st Year Analyst (79) $150
  • Intern/Summer Analyst (73) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
kanon's picture
kanon
99.0
3
BankonBanking's picture
BankonBanking
99.0
4
Secyh62's picture
Secyh62
99.0
5
DrApeman's picture
DrApeman
98.9
6
Betsy Massar's picture
Betsy Massar
98.9
7
dosk17's picture
dosk17
98.9
8
GameTheory's picture
GameTheory
98.9
9
CompBanker's picture
CompBanker
98.9
10
Jamoldo's picture
Jamoldo
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”